WOBURN, Mass.–(BUSINESS WIRE)–Spear Bio Inc., a biotechnology company enabling the measurement of protein molecules down to dozens of copies with ubiquitous qPCR equipment, announced the successful closing of its $45 million Series A financing.
Empowering individuals with knowledge, fostering healthier lifestyles, and fostering a community dedicated to diabetes awareness and prevention. Together, we’re shaping a healthier future.
Subscribe To Us
By submitting via this part of the website you are granting us permission to store and process your data according to our Standard privacy policy
© 2024 Diabetes Prevention Awareness Center.